Correlation of OCTN2 with the chemosensitivity of prostate cancer cells to oxaliplatin
- VernacularTitle:OCTN2与前列腺癌细胞对奥沙利铂化疗敏感性的相关性
- Author:
Lei CHU
1
,
2
;
Bin XU
3
;
Dehou SHA
4
;
Lei WANG
2
;
Guangzhou CHENG
2
;
Jidong ZHANG
5
Author Information
1. Dept. of Urology，the Affiliated Tengzhou Hospital of Xuzhou Medical University，Shandong Zaozhuang 277500，China
2. Dept. of Urology，the Affiliated Tengzhou Central People’s Hospital of Jining Medical University，Shandong Zaozhuang 277500，China
3. Institute of Traditional Chinese Medicine Innovation，Shandong University of Traditional Chinese Medicine，Jinan 250355，China
4. Dept. of Clinical Laboratory，Maternal and Child Health Care Hospital of Zaozhuang，Shandong Zaozhuang 277100，China
5. Dept. of Laboratory，the Affiliated Tengzhou Central People’s Hospital of Jining Medical University，Shandong Zaozhuang 277500，China
- Publication Type:Journal Article
- Keywords:
novel organic cation transporter 2;
oxaliplatin;
prostate cancer cell;
chemosensitivity
- From:
China Pharmacy
2023;34(12):1468-1472
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the correlation of novel organic cation transporter 2 （OCTN2） with the chemosensitivity of prostate cancer cells to oxaliplatin. METHODS Tumor samples of patients receiving radical prostatectomy were collected， and OCTN2 protein was detected with immunohistochemistry； the primary cells of the specimen were cultivated to obtain prostate cancer cell line. Inductively coupled plasma mass spectrometry was used to detect the uptake of low concentration （0.1 μmol/L） of oxaliplatin by cancer cells. Real-time PCR and Western blot were used to detect the mRNA and protein expressions of OCTN2 in cancer cells； the prostate cancer cells with the highest and lowest expression of OCTN2 protein were selected， and IC50 of oxaliplatin to prostate cancer cells was analyzed by ATP-TCA method. The inhibitory rate of plasma peak concentration of oxaliplatin （50 μmol/L） to prostate cancer cells was detected by MTT assay. Spearman method was used to analyze the relationship of the uptake of oxaliplatin by prostate cancer cells with inhibitory rate of oxaliplatin to prostate cancer cells and 505916443@qq.com mRNA expressions of OCTN2. RESULTS OCTN2 was located on the membrane of cancer cells， and the uptake of zjdtztougao@163.com oxaliplatin by cancer cells was 0.283±0.264 （n＝12）mRNA and protein expression of OCTN2 varied significantly among different cancer cells. The sensitivity of cancer cells with high expression of OCTN2 to oxaliplatin （IC50 of 4.61 μmol/L） was higher than that of cancer cells with lower expression of OCTN2 （IC50 of 26.23 μmol/L）. The inhibitory rate of oxaliplatin to cancer cells was （25.4±10.8）% （n＝12）. There was a correlation between the uptake of oxaliplatin by prostate cancer cells and the inhibition rate of oxaliplatin to prostate cancer cells and mRNA expression of OCTN2 （P＜0.05）. CONCLUSIONS High-expressed OCTN2 may promote the uptake of oxaliplatin by prostate cancer cells， and its expression can serve as a reference for predicting the sensitivity of prostate cancer cells to oxaliplatin chemotherapy.
